L'intérêt à découvert pour Insmed donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Insmed. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Insmed (NASDAQ:INSM) Stock, Rapport sur les intérêts à découvert

Insmed

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Insmed Inc

INSMED ORD

—Data Presented at the CHEST 2024 Annual Meeting—
BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from these subgroup analyses can be found <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4272617-1&amp;h=1623866854&amp;u=https%3A%2F%2Finvestor.insmed.com%2Fevents%3Fitem%3D127&amp;a=HERE">HERE</a>. These data were presented at the CHEST 2024 Annual Meeting, held October 6-9 in Boston, along with several other presentations from across Insmed's respiratory portfolio.

Biotech

News

General

INSM

Insmed Inc Presents New Subgroup Analyses From Landmark Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis Demonstrate Consistency With Overall Trial Population Results At The CHEST 2024 Annual Meeting

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $72 to $74.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Insmed, Raises Price Target to $74

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 7.39% on an annualized basis producing an average annual return of 18.6%. Currently, Insmed has a market capitalization of $12.71 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $561.05 today based on a price of $73.95 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726851688_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years

Looking for broad exposure to the Small Cap Value segment of the US equity market? You should consider the JPMorgan BetaBuilders U.S. Small Cap Equity ETF (ARCA:BBSC), a passively managed exchange traded fund launched on 11/16/2020.
The fund is sponsored by J.P. Morgan. It has amassed assets over $520.35 million, making it one of the average sized ETFs attempting to match the Small Cap Value segment of the US equity market.
<h2>Why Small Cap Value</h2>
Small cap companies have market capitalization below $2 billion. They usually have higher potential than large and mid cap companies with stocks but higher risk.
While value stocks have lower than average price-to-earnings and price-to-book ratios, they also have lower than average sales and earnings growth rates. Value stocks have outperformed growth stocks in nearly all markets when you consider long-term performance, growth stocks are more likely to outpace value stocks in strong bull markets.
<h2>Costs</h2>
Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF&#39;s expense ratio.
Annual operating expenses for this ETF are 0.09%, making it one of the least expensive products in the space.
It has a 12-month trailing dividend yield of 1.48%.
<h2>Sector Exposure and Top Holdings</h2>
Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund&#39;s holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation to the Financials sector--about 19.90% of the portfolio. Healthcare and Industrials round out the top three.
Looking at individual holdings, Jpmorgan Us Govt Mmkt Fun accounts for about 1.50% of total assets, followed by Insmed Inc Common Stock (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/insm#NASDAQ">INSM</a>) and Carpenter Technology (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crs#NYSE">CRS</a>).
The top 10 holdings account for about 5.66% of total assets under management.
<h2>Performance and Risk</h2>
BBSC seeks to match the performance of the MORNINGSTAR US SML CP TRG MRK EXP EXT ID before fees and expenses. The Morningstar US Small Cap Target Market Exposure Extended Index is a free-float adjusted, market-cap weighted index that targets small cap securities traded in the U.S.
The ETF has gained about 7.42% so far this year and it&#39;s up approximately 20.46% in the last one year (as of 09/16/2024). In the past 52-week period, it has traded between $48.58 and $67.50.
The ETF has a beta of 1.08 and standard deviation of 23.45% for the trailing three-year period. With about 796 holdings, it effectively diversifies company-specific risk.
<h2>Alternatives</h2>
JPMorgan BetaBuilders U.S. Small Cap Equity ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, BBSC is an excellent option for investors seeking exposure to the Style Box - Small Cap Value segment of the market. There are other additional ETFs in the space that investors could consider as well.
The Avantis U.S. Small Cap Value ETF (ARCA:AVUV) and the Vanguard Small-Cap Value ETF (ARCA:VBR) track a similar index. While Avantis U.S. Small Cap Value ETF has $12.95 billion in assets, Vanguard Small-Cap Value ETF has $29.58 billion. AVUV has an expense ratio of 0.25% and VBR charges 0.07%.
<h2>Bottom-Line</h2>
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.
<a href="https://www.zacks.com/stock/news/2336240/should-jpmorgan-betabuilders-u-s-small-cap-equity-etf-bbsc-be-on-your-investing-radar?cid=CS-BENZ-FT-style_box_etf-2336240">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Mid Cap

Sector ETFs

Dividends

Small Cap

Markets

ETFs

AVUV

BBSC

Should JPMorgan BetaBuilders U.S. Small Cap Equity ETF Be on Your Investing Radar?

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has fallen 9.3% since its last report. The company recently reported that it has 12.23 million shares sold short, which is 7.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726502419_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 6.00%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(INSM) - Analyzing Insmed's Short Interest

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 7.82% on an annualized basis producing an average annual return of 18.36%. Currently, Insmed has a market capitalization of $12.29 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $5,347.05 today based on a price of $71.49 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725984016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today

Cantor Fitzgerald analyst Josh Schimmer reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Insmed

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $90 price target.

HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 7.94% on an annualized basis producing an average annual return of 18.82%. Currently, Insmed has a market capitalization of $13.31 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $5,609.70 today based on a price of $77.45 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724680820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today

Watching Shares Of Insmed; Traders Circulating Mentions Of Company In Popular M&A Blog

Truist Securities analyst Nicole Germino maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and lowers the price target from $88 to $85.

Truist Securities Maintains Buy on Insmed, Lowers Price Target to $85

TD Cowen analyst Ritu Baral maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $75 to $98.

TD Cowen Maintains Buy on Insmed, Raises Price Target to $98

UBS analyst Trung Huynh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $78 to $84.

UBS Maintains Buy on Insmed, Raises Price Target to $84

Stifel analyst Stephen Willey maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $74 to $88.

Stifel Maintains Buy on Insmed, Raises Price Target to $88

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 5 years by 21.62% on an annualized basis producing an average annual return of 34.24%. Currently, Insmed has a market capitalization of $11.26 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 5 years ago, it would be worth $449.68 today based on a price of $69.00 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723145498_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today

WIIM

Insmed shares are trading lower after the company reported mixed Q2 financial results.

Guidance

Health Care

Insmed Reiterates 2024 Global Arikayce Revenue Guidance Of $340M-$360M, Reflecting Double-digit Growth Compared To 2023

Insmed Q2 2024 GAAP EPS $(1.94) Misses $(1.24) Estimate, Sales $90.340M Beat $87.950M Estimate

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 4.66% on an annualized basis producing an average annual return of 15.55%. Currently, Insmed has a market capitalization of $12.25 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $423.45 today based on a price of $75.12 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721233817_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on Insmed (INSM – Research Report). The associated price target remains the...

Insmed's Brensocatib Poised for Market Leadership: A Buy Rating Amidst Unthreatening Competition

Columbia Acorn Fund Q2 2024 Investment Commentary

Stifel Nicolaus analyst Stephen Willey has maintained their bullish stance on INSM stock, giving a Buy rating on August 29. Stephen Willey has give...

Insmed Maintains Competitive Edge Amid Lackluster Trial Results for Rival Drug BI 1291583

Tracking Baker Brothers Portfolio - Q2 2024 Update

Barclays analyst Leon Wang maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $90.00. The company's shares ...

Barclays Sticks to Their Buy Rating for Insmed (INSM)

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 9/11/2024, According to Top Analysts

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Insmed (INSM – Research Report), with a price target of $75.00...

Evercore ISI Remains a Buy on Insmed (INSM)

Janus Henderson Global Life Sciences Fund Q2 2024 Commentary

Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2024 Commentary

Voya Small Company Strategy Q2 2024 Commentary

ABBV

ABCL

ACAD

AKRO

AMGN

ARGNF

ARGX

ASND

ATKR

AVDL

AZNCF

BCRX

BCYC

BEIGF

BGNE

BHVN

BRKR

CHDN

CIGI

CVNA

ETNB

EWTX

EXAS

FDMT

FIVE

FTAI

FTAIM

FTAIN

FTAIO

FTAIP

GMED

IMCR

INCY

KYMR

MDGL

NONOF

NTRA

NVSEF

RARE

REPL

RGEN

ROIV

RVMD

RVMDW

RYAN

RYTM

SMCI

SNYNF

SPXC

SRPT

STOK

TECH

UTHR

VRTX

ZETA

Press Releases

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Offerings

Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025

Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference

Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024

Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update

New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

Comments

Insmed

Intérêt court

Insmed (NASDAQ:INSM) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL